Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Clinical trial NCT03106779 · COMPLETED
Trial details
- NCT number
- NCT03106779
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-26
- Primary completion
- 2020-05-25
- Enrollment
- 233
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.